PBS Biotech’s Post

"It’s less of a business partnership and more of a mission partnership."    We're thrilled to collaborate with visionary leaders like 🎗️Ohad Karnieli Karnieli from Adva Biotechnology. In this video, Ohad shares what excites him most about our partnership: advancing Cell and Gene Therapy through innovation and teamwork.   By combining Adva’s X3® cell manufacturing platform with Xiogenix’s ARES™ X20 fill-and-finish system, we’re delivering a more flexible, end-to-end solution that simplifies processes, enhances precision, and brings life-saving therapies closer to patients.   At Xiogenix, we’re committed to driving innovation through collaboration and shaping the future of Cell and Gene Therapy. Learn more about our mission and technology at www.xiogenix.com   Allie Schroeder, Sami Reimer, Rachel Bahr, Jerry Jendusa 🎗 Ofra Toledo, #CellAndGeneTherapy #InnovationInMedicine #Collaboration #Xiogenix #AdvaBiotechnology #MaximizingLife

At #JPM2025 #JPM25? Join us tomorrow to learn more about our mission and the progress we’re making towards unlocking the potential of gene therapy for all.

The biotech industry is evolving at rapid speed, and staying ahead demands a proactive approach. In this on-demand webinar, our CTO, Hanna P. Lesch, along with industry experts share their practical insights to help you navigate the challenges and seize opportunities in cell and gene therapy. By watching, you'll learn: 🔍 Key strategies to secure vital funding in a competitive market 🏆 How to refine your operations while maintaining top-notch quality and regulatory compliance 🌐 How to overcome hurdles to get your therapies approved and into the market 💰 Tips for mastering the complexities of pricing to ensure your therapies reach patients and remain profitable Watch on-demand below. https://lnkd.in/e7a-zrZx #GeneTherapy #CGT

Modular facilities, driven by the rise of cell and gene therapies, continuous manufacturing, and single-use technologies, help biomanufacturers meet clinical demands. Learn how we partnered with Siemens to create automation and digitization solutions for streamlined modular processing. Watch the video below and learn more in our white paper: https://sar.to/1xs07 #SimplifyingProgress #InThisTogether #Bioprocessing

📹 In this Movers & Shakers interview from Meeting on the Mesa, Jason C. Foster (Ori Biotech) introduces the CGT manufacturing technology company, before exploring the challenges associated with the circular supply chain associated with autologous therapies. 💰 Jason goes on to discuss what's needed to bring investment back to the cell and gene therapy space, summarizing some key takeaways from the meeting. ▶ Want to see more? Catch up with many more insights from the show floor, here: https://lnkd.in/eF-SM8pq

Are you working within cell and gene therapy development? Check out the event from Technology Networks airing Nov 13th, including Ryan Nai's presentation on #plasmid and double-stranded #DNA analyses using the latest kit from #SCIEX, streamlining purity determination and size estimation. 💥 #mRNA #vaccines #SCIEX #CE #capillaryelectrophoresis

VERDOT is excited to announce the €10 million partnership with BioProcess360 Partners, marking a significant step in our journey to scale globally and drive innovation in bioprocessing. The #bioprocessing and #lifesciences industries are undergoing significant transformations. As new molecular entities like nucleic acids and gene therapies redefine the landscape, VERDOT remains committed to helping clients overcome challenges and seize opportunities. This investment brings invaluable expertise and networks to strengthen our global presence and scale our capabilities. Together with #QualiumInvestissement and #LauxeraCapitalPartners, we aim to deliver innovative solutions that reduce time to market, improve process efficiency, and support access to groundbreaking therapies. 🚀 Here’s to the next phase of growth and innovation! For further information, visit: [https://lnkd.in/ey8gtB45] #VERDOT #LifeSciences #Bioprocessing #Innovation #GrowthStrategy #Biopharma #Partnership

My first article from the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa... It's based on a fantastic panel discussion around decentralized manufacturing for CGTs and what regulators expect of companies looking to use decentralized models to bring cell therapies to patients.

This has to be the biggest news in the Bioprocessing industry so far in 2025! Thrilled is an under statement, #verdot has market leading technology in the field of downstream bioprocessing with columns and hardware. With a focus on newer modalities like mRNA and Gene Therapy together with mAbs. We are proud to work alongside #QualiumInvestissement and #LauxeraCapitalPartners. Jacques Pancrazi, Jean-Brice Lachaux, Pierre Moustial, Alex Slack, Edoardo Fracchia, Alessandra Malaval, Charles Ruban, Brian Gerwe, Lorraine Attridge, Sebastien MAGNAUD, Sebastien Lefebvre, David LE FUR, Bradford Beatty, Chris Major

💡 Did you know that incremental viral vector yield improvements can lead to reduced COGS and significant long-term savings? Cell and Gene Therapy (CGT) is a rapidly growing industry and manufacturing scale-up is critical for commercial success. However, process inefficiencies and high manufacturing costs limit broad applicability and patient affordability. Virica uses bioprocess modeling to break down key cost drivers of AAV and LV manufacturing and commercial savings incorporating enhancer technologies such as our Viral Sensitizers (VSEᵀᴹ). ✔ Check out our latest read on how Virica leverages BioSolve bioprocess modeling to enable informed decision-making to drive down manufacturing costs of life-saving CGTs. 👉 Link to Article: https://lnkd.in/dVkvuFh2 Want to learn more? 📅 We are attending Cell and Gene on the Mesa next week! 🤝 Connect with us through partnering: https://lnkd.in/deKPvPXG Or through our website: https://lnkd.in/dZajZX2V #biomanufacturing #bioprocess #innovation #cgtreads